We previously reported a 50% (95% CI = 33-76%) 5 year event-free survival (EFS) rate for 23 patients with Although autologous stem cell transplantation (ASCT) is considered standard therapy for most patients with relapsed or refractory Hodgkin's disease (HD), the optimal highdose chemotherapy regimen is unknown.
strates that DICEP re-induction prior to HDM/ASCT is feasible. The preliminary data are sufficiently encouraging to warrant a multicenter phase II or a phase III trial evaluating DICEP followed by HDM/ASCT as salvage therapy for HD. Bone Marrow Transplantation (2000) 26, 383-388. Keywords: Hodgkin's disease; hematopoietic stem cell transplantation Although autologous stem cell transplantation (ASCT) is considered standard therapy for most patients with relapsed or refractory Hodgkin's disease (HD), the optimal highdose chemotherapy regimen is unknown. 1, 2 Most high-dose regimens involve drug combinations because combinations of non-cross-resistant agents may produce greater antitumor efficacy than single agents. Melphalan has a steep cytotoxic dose-response curve in vitro, 3 and is commonly used in these high-dose combination regimens at a dose of 140 mg/m 2 . However, its efficacy might decrease when its dose is lowered from the maximally tolerated single agent dose of 200-220 mg/m 2 to that used in multi-agent regimens.
We previously reported a 50% (95% CI = 33-76%) 5 year event-free survival rate for 23 patients with relapsed or refractory HD who were treated with single agent highdose melphalan (HDM) and ASCT. 4 This rate is similar to that reported for multi-agent high-dose chemotherapy regimens. 1, 2, 5 We found that bulky disease or an initial remission duration of less than 1 year were adverse prognostic factors for HDM. 4 Since 1995, patients with these factors have been treated at our center with double highdose therapy consisting of dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by HDM/ASCT. DICEP was chosen because it has been studied in numerous patients and shown to have acceptable morbidity and mortality rates. 6, 7 The unique feature of this high-dose regimen is that it is not myeloablative and, therefore, does not require autologous blood or bone marrow stem cell support. 8 Moreover, it can mobilize blood stem cells for collection by apheresis. 9, 10 Although there are few data reported for DICEP in HD, this regimen is very similar to CBV (cyclophosphamide 6 g/m 2 , BCNU 300 mg/m 2 , and etoposide 750 mg/m 2 ) which has been extensively studied in HD.
11 DICEP was, therefore, used both for tumor cytoreduction and for autologous blood stem cell mobilization. The purpose of the present study was to determine if the use of DICEP re-induction therapy is associated with improved event-free (EFS) and overall survival (OAS) for patients treated with HDM/ASCT.
Patients and methods

Patients
Between February 1981 and June 1999, 46 consecutive patients with relapsed (n = 35) or refractory (n = 11) HD were treated with HDM and ASCT. Twenty patients were treated prior to 1995 and 26 were treated after 1995. Characteristics of these patients are listed in Table 1 . This report includes data from 23 patients who were previously reported in 1997. 4 Eligibility for HDM required adequate cardiac, pulmonary, hepatic, and renal function. Chemosensitivity was defined as at least a 50% response to salvage chemotherapy administered after disease progression but before marrow harvesting or blood stem cell mobilization.
The HDM protocol received ethical approval by our Institutional Review Board. Due to the extensive body of literature concerning the toxicity profile of DICEP chemotherapy, 6, 7 and efficacy data of the closely related CBV regimen for HD, 11 our ethics committee felt that a formal phase II protocol was not required for DICEP. The DICEP data were collected prospectively as a quality assurance project. All patients gave written informed consent prior to undergoing bone marrow harvest, or prior to receiving either G-CSF alone, cyclophosphamide plus G-CSF or DICEP plus G-CSF for blood stem cell mobilization.
Stem cell harvesting and reinfusion
Patients treated before 1994 received non-cryopreserved autologous marrow while those treated after 1994 received cryopreserved autologous blood stem cells. Methods of + counts. 12 Only a single cycle of DICEP was used. Vascular access for apheresis was obtained with an internal jugular or femoral dual lumen catheter. A Cobe Spectra Cell Separator (Cobe Laboratories, Engelwood, CO, USA) was used for collection of blood stem cells. The apheresis product was cooled in a controlled-rate freezer using 10% DMSO as a cryoprotectant and was stored in liquid nitrogen. The autograft for one patient was processed with the CellPro (Bothell, WA, USA) CEPRATE SC System prior to cryopreservation.
High-dose conditioning
Melphalan 140-200 mg/m 2 was infused on day -1 over 5 min, and was followed immediately with i.v. hydration and diuresis. Patients received HDM the same day as bone marrow harvest or within 3 weeks of blood stem cell collection. Bone marrow or blood stem cells were infused on day 0, approximately 24 h after HDM. Protective isolation procedures have never been used for patients receiving ASCT at our center. Following administration of DICEP, patients were usually assessed every 1-2 days as outpatients and readmitted to hospital if they developed febrile neutropenia.
Evaluation criteria
Overall survival was defined as the number of months from ASCT (day 0) until death from any cause, or until the time of last follow-up. Event-free survival was defined as the number of months from ASCT until disease progression or death. Overall and event-free survival distributions were estimated using the method of Kaplan and Meier. 13 Factors included in univariate and multivariate analysis were age at transplant, initial remission duration Ͻ1 year, relapsed or refractory disease status, number of prior failed chemotherapy regimens, prior radiotherapy, bulk Ͼ5 cm, extranodal disease at relapse, B symptoms at relapse, post-ASCT radiotherapy, and DICEP re-induction therapy. Cox proportional hazards models were constructed for both event and for death. Non-hematologic toxicity was graded by the method described by Bearman et al.
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Results
Treatment received
One patient received 140 mg/m 2 and a second received 160 mg/m 2 as part of an initial phase I study. The remaining 44 patients received 200 mg/m 2 of melphalan. Eighteen patients received non-cryopreserved autologous marrow and 28 received cryopreserved autologous blood stem cells. Blood stem cells were used for all 21 DICEP patients and for seven patients who did not receive DICEP (P Ͻ 0.001).
Methods of blood stem cell mobilization included G-CSF alone (n = 2), cyclophosphamide 2 g/m 2 plus G-CSF (n = 5), or DICEP plus G-CSF (n = 21). Post-transplant involved field radiotherapy (IFRT) 35 Gy in 20 fractions to sites of residual abnormality or sites of previous bulky disease was used for 13 DICEP patients and 10 patients who did not receive DICEP. The use of IFRT was not significantly different between patients treated with DICEP and those who were not (P = 0.236).
Event-free and overall survival
The median follow-up post ASCT was 17 months (3-48) for the 21 patients who received DICEP and 37 months (4-185) for the other 25 patients. Figure 1 illustrates the EFS and OAS for all 46 patients. For all 46 patients, the projected 5 year EFS was 52% (95% CI = 38-72%) and OAS was 57% (95% CI = 40-82%). By univariate analysis, factors associated with relapse were failing Ͼ2 prior chemotherapy regimens (P = 0.0009) and prior radiotherapy (P = 0.022). Factors not associated with relapse were age at transplant, initial remission duration Ͻ1 year, relapsed or refractory disease status, failing Ͼ1 prior chemotherapy regimen, bulk Ͼ5 cm, extranodal disease at relapse, B symptoms at relapse, post-ASCT radiotherapy, and DICEP re-induction therapy. The 2 year EFS was 71% (95% CI = 48-100%) for patients who received DICEP and 48% (95% CI = 32-72%) for patients who did not receive DICEP (P = 0.096). By univariate analysis, the only factors associated with death were failing Ͼ2 prior chemotherapy regimens (P = 0.0005), prior radiotherapy (P = 0.0261), and initial CR Ͻ1 year (P = 0.0155). The use of DICEP was not associated with overall survival by univariate analysis (P = 0.089). The 2 year OAS was 87% (95% CI = 70-100%) for patients who received DICEP and 60% (95% CI = 44-83%) for patients who did not receive DICEP. Tables 2 and 3 show the Cox proportional hazards models for event and for death, respectively. Even if all factors were included in the model (prior radiotherapy, number of failed chemotherapy regimens, length of initial remission, refractory vs relapsed disease status, disease bulk, extranodal relapse, B symptoms at relapse, use of DICEP re-induction, post-transplant radiotherapy), re-induction with DICEP remained independently associated with improved event-free (P Ͻ 0.0001) and overall survival (P = 0.0003).
Toxicity
No patient treated with DICEP or with HDM/ASCT experienced early treatment-related mortality (within 100 days post ASCT) or life-threatening Bearman 14 grade III regimen-related toxicity. DICEP was well tolerated except for a 71% febrile neutropenia rate. No patient developed sepsis syndrome. Six DICEP patients experienced mild to moderate mucositis. Grade II mucositis was the most frequent and severe toxicity following HDM/ASCT. 
Results of DICEP
The 21 patients who received DICEP ranged in age from 19 to 50 years (median = 33). Response assessment included 18 partial responses (86%), two stable disease, and one progressive disease. The patients required from 0-6 units (median = 2 units) of RBC and 0-5 (median = 1) platelet transfusions. The median day to neutrophil recovery Ͼ0.5 ϫ 10 9 /l was 17 (range [15] [16] [17] [18] [19] [20] , and to platelet recovery Ͼ20 ϫ 10 9 /l was also day 17 (range [14] [15] [16] [17] [18] [19] [20] [21] [22] . The number of inpatient nights ranged from 4 to 20 (median = 12).
All 
Discussion
This study suggests a benefit of two cycles of high-dose salvage chemotherapy for patients with Hodgkin's disease. By multivariate analysis, it identified an independent association between the use of DICEP re-induction chemotherapy and improved EFS and OAS for consecutive patients undergoing HDM/ASCT. In addition, the double high-dose treatment was well tolerated with no severe toxicity. As we have previously reported, DICEP mobilized autologous blood stem cells extremely well. 12 This result is supported by the findings of a randomized controlled trial which compared DICEP plus G-CSF (C = 4.5 g/m 2 , E = 1200 mg/m 2 , P = 135 mg/m 2 ) to G-CSF alone for peripheral blood stem cell mobilization in 121 patients with stages II-IV breast cancer. 15 All randomized breast cancer patients subsequently received high-dose cyclophosphamide, thiotepa and BCNU with ASCT. Not only did the DICEP plus G-CSF regimen result in superior stem cell mobilization and engraftment, it was also associated with a significantly lower 2 year actuarial progression rate (25% vs 52%, P = 0.02). Even by multivariate analysis, DICEP plus G-CSF was associated with improved progression-free survival (P Ͻ 0.05) for these patients with breast cancer. 15 Our study has several limitations. Accrual was slow, particularly for patients treated before 1995. The sample size was small reflecting a small referral base to a single center. This small sample size may have affected our ability to detect non-treatment-related factors that influenced patient outcome. We did detect an association between EFS and disease bulk disease as well as prior radiotherapy. The predictive value of disease bulk has been previously reported. 4, 16, 17 We did not, however, detect an effect of other possible adverse predictive factors for EFS such as an initial remission duration Ͻ1 year, 4, 18 B symptoms at relapse, 17, 18 extranodal relapse, 18, 19 poor performance status, 11, 18 number of failed prior chemotherapy regimens 11, 16, 17, 19 and chemoresistance. 20 Perhaps all of these factors influence outcome, but only a very large study will be able to determine the relative importance of this influence. Even a recent effort by the European Bone Marrow Transplant Group could not detect an association between progression-free or overall survival and any of these putative predictive factors in 139 patients with HD receiving ASCT in first relapse. 21 When interpreting the impact of DICEP re-induction in this study, one must recognize that 86% of the patients treated with DICEP had failed only one prior chemotherapy regimen. Armitage and colleagues 22 reported a 4 year disease-free survival rate of 44% vs 33% vs 21% (P = 0.04) for 71 HD patients who had failed one, two or three prior chemotherapy regimens, respectively. 22 We, however, could not identify any significant difference in EFS or OAS between patients who had failed one or two prior regimens. Although several studies, including ours, have suggested worse outcome for patients who have failed three or more prior regimens, most have not shown a difference in outcome for patients failing one vs two prior chemotherapy regimens. 11, 16, 17, 19 Chopra and colleagues 16 actually found that patients transplanted in second or third relapse had a better progression-free survival rate than those transplanted in first relapse. In the Chopra study, worse OAS was only reported for patients who had failed three or more lines of treatment, not for those who had failed two prior treatments. 16 Two-year EFS rates reported for HD patients transplanted in first relapse range from 40% to 64%. 11, 18, [21] [22] [23] [24] This includes EBMT data on 139 HD patients transplanted in first relapse who achieved 2-and 5-year progression-free survival rates of approximately 50% and 45%, respectively. 21 The 2 year EFS rate of 71% experienced by our patients treated with DICEP then HDM/ASCT generally compares favorably with these other reports.
A further limitation of the study is that it utilized historical controls and is, therefore, subject to the usual criticisms of bias inherent in any such non-randomized, historical comparison. For example, it is probable that referral patterns and patient selection changed over time. Patients transplanted after 1995 were accrued faster, were less heavily pre-treated and were more likely to have bulky disease. It is probable that the historical controls were more likely to receive radiotherapy or second-line standard-dose chemotherapy at relapse. This salvage treatment may have debulked the disease prior to HDM/ASCT, but may not have resulted in complete remission. Since accrual was faster after 1995, it is possible that patient selection was, in fact, less stringent during this time. For example, it is possible that patients with significant disease bulk were not referred for ASCT prior to 1995. Bone marrow involved by Hodgkin's disease was an exclusion factor for ASCT in our center prior to, but not after 1995.
Another limitation of the study is the non-uniform treatment of the patients. The HDM/ASCT protocol was similar between the groups, although two patients received Ͻ200 mg/m 2 HDM as part of an initial multicenter phase I study. Of note, one of these patients continues event-free 18 years after ASCT. All DICEP patients received blood stem cell support whereas 18 of the remaining 25 patients received bone marrow support. No study has proven that EFS or OAS is better for autologous blood stem cell transplantation than for autologous bone marrow transplantation. 5 In fact, EBMT data from 1299 HD patients demonstrated superior 4 year OAS (65% vs 53%, P = 0.02) and EFS (60% vs 41%, P = 0.016) for patients who received autologous bone marrow compared to blood stem cell transplantation. 25 There may have been other differences in supportive care over time, but since there was no early treatment-related mortality in either group, these differences did not affect the survival of the patients.
The above differences in disease and treatment characteristics between the groups may confound the results of the study. The results are preliminary and are based on a relatively small number of patients. Nevertheless, multivariate analysis demonstrated that the strategy of risk-adapted DICEP-HDM/ASCT used after 1995 did result in superior EFS and OAS than HDM/ASCT alone even when controlling for other prognostic factors. This study demonstrates that risk-adapted DICEP re-induction is feasible and the preliminary data are sufficiently encouraging to warrant a large multicenter phase II trial to further evaluate DICEP followed by HDM/ASCT as salvage therapy for HD. If such a trial also gives encouraging results, then a phase III study comparing DICEP-HDM/ASCT to CBV or BEAM will be indicated.
